Ischemia - Pipeline Review, H2 2015

Date: December 16, 2015
Pages: 223
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: IFC8618CEE0EN
Leaflet:

Download PDF Leaflet

Ischemia - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Ischemia - Pipeline Review, H2 2015’, provides an overview of the Ischemia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Ischemia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Ischemia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Ischemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Ischemia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Ischemia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Ischemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Ischemia Overview
Therapeutics Development
Pipeline Products for Ischemia - Overview
Pipeline Products for Ischemia - Comparative Analysis
Ischemia - Therapeutics under Development by Companies
Ischemia - Therapeutics under Investigation by Universities/Institutes
Ischemia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Ischemia - Products under Development by Companies
Ischemia - Products under Investigation by Universities/Institutes
Ischemia - Companies Involved in Therapeutics Development
Alize Pharma SAS
Amyndas Pharmaceuticals LLC
AnGes MG, Inc.
Apceth GmbH & Co. KG
Athersys, Inc.
Baxalta Incorporated
Caladrius Biosciences, Inc.
Cellmid Limited
CoDa Therapeutics, Inc.
CohBar, Inc.
Cynata Therapeutics Limited
DNAVEC Corporation
GlaxoSmithKline Plc
Hemostemix Ltd
IntelliCell BioSciences Inc.
Juventas Therapeutics, Inc.
Kasiak Research Private Limited
Lixte Biotechnology Holdings, Inc.
Mesoblast Limited
Miltenyi Biotec GmbH
Mirrx Therapeutics A/S
Multi Gene Vascular Systems Ltd
NoNO, Inc.
Nyken BV
Pathfinder Cell Therapy, Inc.
Pharmicell Co., Ltd.
Pluristem Therapeutics Inc.
Protagenic Therapeutics Inc.
ReNeuron Group Plc
Sihuan Pharmaceutical Holdings Group Ltd.
Stempeutics Research Private Limited
Targazyme, Inc.
Taxus Cardium Pharmaceuticals Group Inc.
TikoMed AB
U.S. Stem Cell, Inc.
Vericel Corporation
ViroMed Co., Ltd.
Ischemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AB-002 - Drug Profile
ACP-01 - Drug Profile
AdipoCell - Drug Profile
Alda-1 - Drug Profile
Alecmestencel-T - Drug Profile
alferminogene tadenovec - Drug Profile
AntimiR-199a - Drug Profile
ASCT-01 - Drug Profile
Autologous Vascular Cells Therapy - Drug Profile
AZP-531 - Drug Profile
beperminogene perplasmid - Drug Profile
bucillamine - Drug Profile
CD-52 - Drug Profile
Cell Therapy for Critical Limb Ischemia - Drug Profile
Cell Therapy for Ischemia - Drug Profile
Cell Therapy for Ischemia - Drug Profile
Cellgram for Severe Lower Limb Ischemia - Drug Profile
Cinepazide Mesylate - Drug Profile
CLBS-12 - Drug Profile
CMK-103 - Drug Profile
daprodustat - Drug Profile
DVC1-0101 - Drug Profile
EP-80317 - Drug Profile
Gene Therapy for Critical Limb Ischemia and Peripheral Arterial Disease - Drug Profile
Humanin - Drug Profile
ixmyelocel-T - Drug Profile
JVS-100 - Drug Profile
JVS-200 - Drug Profile
LB-100 - Drug Profile
LB-102 - Drug Profile
MicroRNA for Ischemia - Drug Profile
MPC-25IC - Drug Profile
MultiGeneAngio - Drug Profile
MultiStem - Drug Profile
NYK-1112 - Drug Profile
Oligonucleotide to Inhibit miRNA-26 for Ischemic Cardiovascular Disease - Drug Profile
Oligonucleotides for Immunology, Oncology, Infectious and Cardiovascular Disorders - Drug Profile
Pathfinder Cells - Drug Profile
Peptagon - Drug Profile
PLX-PAD - Drug Profile
PMC-6 - Drug Profile
Protein to Agonize LRP5 and LRP6 for Myocardial Infarction and Critical Limb Ischemia - Drug Profile
PT-00114 - Drug Profile
Recombinant Peptide to Activate FPR2 for Ischemia Reperfusion Injury and Myocardial Ischaemia - Drug Profile
Recombinant Protein for Critical Limb Ischemia - Drug Profile
Recombinant Protein for Ischemia - Drug Profile
Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology - Drug Profile
Refacell-CLI - Drug Profile
Rejuveinix - Drug Profile
ReN-009 - Drug Profile
Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion Injury - Drug Profile
Small Molecules for Ischemia and Reperfusion Injury - Drug Profile
Small Molecules for Renal Failure and Renal Ischemia - Drug Profile
Small Molecules to Activate Heat Shock Protein H11 Kinase for Myocardial Ischemia - Drug Profile
Small Molecules to Antagonize TRPM7 for Myocardial Ischemia and Glaucoma - Drug Profile
Small Molecules to Inhibit Mst1 for Myocardial Ischemia - Drug Profile
Stem Cell Therapy for Cardiovacular Diseases - Drug Profile
Stem Cell Therapy for Cardiovascular Disease - Drug Profile
Stem Cell Therapy for Cardiovascular Diseases - Drug Profile
Stem Cell Therapy for Critical Limb Ischemia - Drug Profile
Stem Cell Therapy to Activate VEGF for Critical Limb Ischemia - Drug Profile
Stempeucel - Drug Profile
Stromal Cell Therapy for Critical Limb Ischemia - Drug Profile
TM-700 - Drug Profile
TZ-101 - Drug Profile
VM-202 - Drug Profile
Ischemia - Recent Pipeline Updates
Ischemia - Dormant Projects
Ischemia - Discontinued Products
Ischemia - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Ischemia, H2 2015
Number of Products under Development for Ischemia - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd.1)
Number of Products under Development by Companies, H2 2015 (Contd.2)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd.1)
Products under Development by Companies, H2 2015 (Contd.2)
Products under Development by Companies, H2 2015 (Contd.3)
Products under Investigation by Universities/Institutes, H2 2015
Ischemia - Pipeline by Alize Pharma SAS, H2 2015
Ischemia - Pipeline by Amyndas Pharmaceuticals LLC, H2 2015
Ischemia - Pipeline by AnGes MG, Inc., H2 2015
Ischemia - Pipeline by Apceth GmbH & Co. KG, H2 2015
Ischemia - Pipeline by Athersys, Inc., H2 2015
Ischemia - Pipeline by Baxalta Incorporated, H2 2015
Ischemia - Pipeline by Caladrius Biosciences, Inc., H2 2015
Ischemia - Pipeline by Cellmid Limited, H2 2015
Ischemia - Pipeline by CoDa Therapeutics, Inc., H2 2015
Ischemia - Pipeline by CohBar, Inc., H2 2015
Ischemia - Pipeline by Cynata Therapeutics Limited, H2 2015
Ischemia - Pipeline by DNAVEC Corporation, H2 2015
Ischemia - Pipeline by GlaxoSmithKline Plc, H2 2015
Ischemia - Pipeline by Hemostemix Ltd, H2 2015
Ischemia - Pipeline by IntelliCell BioSciences Inc., H2 2015
Ischemia - Pipeline by Juventas Therapeutics, Inc., H2 2015
Ischemia - Pipeline by Kasiak Research Private Limited, H2 2015
Ischemia - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2015
Ischemia - Pipeline by Mesoblast Limited, H2 2015
Ischemia - Pipeline by Miltenyi Biotec GmbH, H2 2015
Ischemia - Pipeline by Mirrx Therapeutics A/S, H2 2015
Ischemia - Pipeline by Multi Gene Vascular Systems Ltd, H2 2015
Ischemia - Pipeline by NoNO, Inc., H2 2015
Ischemia - Pipeline by Nyken BV, H2 2015
Ischemia - Pipeline by Pathfinder Cell Therapy, Inc., H2 2015
Ischemia - Pipeline by Pharmicell Co., Ltd., H2 2015
Ischemia - Pipeline by Pluristem Therapeutics Inc., H2 2015
Ischemia - Pipeline by Protagenic Therapeutics Inc., H2 2015
Ischemia - Pipeline by ReNeuron Group Plc, H2 2015
Ischemia - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H2 2015
Ischemia - Pipeline by Stempeutics Research Private Limited, H2 2015
Ischemia - Pipeline by Targazyme, Inc., H2 2015
Ischemia - Pipeline by Taxus Cardium Pharmaceuticals Group Inc., H2 2015
Ischemia - Pipeline by TikoMed AB, H2 2015
Ischemia - Pipeline by U.S. Stem Cell, Inc., H2 2015
Ischemia - Pipeline by Vericel Corporation, H2 2015
Ischemia - Pipeline by ViroMed Co., Ltd., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Ischemia Therapeutics - Recent Pipeline Updates, H2 2015
Ischemia - Dormant Projects, H2 2015
Ischemia - Dormant Projects (Contd.1), H2 2015
Ischemia - Dormant Projects (Contd.2), H2 2015
Ischemia - Dormant Projects (Contd.3), H2 2015
Ischemia - Dormant Projects (Contd.4), H2 2015
Ischemia - Dormant Projects (Contd.5), H2 2015
Ischemia - Discontinued Products, H2 2015

LIST OF FIGURES

Number of Products under Development for Ischemia, H2 2015
Number of Products under Development for Ischemia - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

Alize Pharma SAS
Amyndas Pharmaceuticals LLC
AnGes MG, Inc.
Apceth GmbH & Co. KG
Athersys, Inc.
Baxalta Incorporated
Caladrius Biosciences, Inc.
Cellmid Limited
CoDa Therapeutics, Inc.
CohBar, Inc.
Cynata Therapeutics Limited
DNAVEC Corporation
GlaxoSmithKline Plc
Hemostemix Ltd
IntelliCell BioSciences Inc.
Juventas Therapeutics, Inc.
Kasiak Research Private Limited
Lixte Biotechnology Holdings, Inc.
Mesoblast Limited
Miltenyi Biotec GmbH
Mirrx Therapeutics A/S
Multi Gene Vascular Systems Ltd
NoNO, Inc.
Nyken BV
Pathfinder Cell Therapy, Inc.
Pharmicell Co., Ltd.
Pluristem Therapeutics Inc.
Protagenic Therapeutics Inc.
ReNeuron Group Plc
Sihuan Pharmaceutical Holdings Group Ltd.
Stempeutics Research Private Limited
Targazyme, Inc.
Taxus Cardium Pharmaceuticals Group Inc.
TikoMed AB
U.S. Stem Cell, Inc.
Vericel Corporation
ViroMed Co., Ltd.
Skip to top


Myocardial Ischemia - Pipeline Review, H2 2016 US$ 2,000.00 Aug, 2016 · 84 pages
Brain Ischemia - Pipeline Review, H2 2016 US$ 2,000.00 Oct, 2016 · 58 pages
Brain Ischemia - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 64 pages
Critical Limb Ischemia - Pipeline Review, H1 2016 US$ 2,000.00 May, 2016 · 150 pages
Ischemia - Pipeline Review, H1 2015 US$ 1,600.00 Jun, 2015 · 231 pages

Ask Your Question

Ischemia - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: